156.13

0.27% -0.42

Palvella Therapeutics Inc (PVLA)

Overview News Price History Discussions Forecast

Palvella Therapeutics Inc stock is traded at $156.13, with a volume of 109.81K. It is down -0.27% in the last 24 hours and up +4.31% over the past month. Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.

Previous Close:

$156.55

Open:

$156.55

24h Volume:

109.81K

Relative Volume:

0.44

Market Cap:

$2.25B

Revenue:

$1.30M

Net Income/Loss:

$-49.30M

P/E Ratio:

-37.45

EPS:

-4.1688

Net Cash Flow:

$-29.10M

1W Performance:

-1.04%

1M Performance:

+4.31%

6M Performance:

+91.48%

1Y Performance:

+238.68%

1-Day Range:

$154.35

$160.33

1-Week Range:

$150.41

$160.33

52-Week Range:

$44.24

$161.38

Palvella Therapeutics Inc Stock (PVLA) Company Profile

Name

Palvella Therapeutics Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

(484) 253-1461

Address

353 W. LANCASTER AVENUE, WAYNE

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

PVLA's Discussions on Twitter

Compare PVLA vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PVLA Palvella Therapeutics Inc	156.13	2.23B	1.30M	-49.30M	-29.10M	-4.1688
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-07-26	Initiated	Mizuho	Outperform
Dec-05-25	Initiated	BTIG Research	Buy
Dec-04-25	Initiated	Craig Hallum	Buy
Nov-19-25	Upgrade	Raymond James	Outperform → Strong Buy
Sep-09-25	Initiated	Oppenheimer	Outperform
Aug-06-25	Initiated	Raymond James	Outperform
Jul-21-25	Initiated	Truist	Buy
Apr-09-25	Initiated	Chardan Capital Markets	Buy
Mar-26-25	Initiated	Stifel	Buy
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Feb-20-25	Initiated	Canaccord Genuity	Buy
Feb-05-25	Initiated	TD Cowen	Buy
Dec-26-24	Initiated	H.C. Wainwright	Buy
Dec-18-24	Initiated	Cantor Fitzgerald	Overweight
Mar-13-20	Upgrade	Robert W. Baird	Neutral → Outperform
Jul-30-19	Downgrade	Robert W. Baird	Outperform → Neutral
May-14-19	Initiated	Robert W. Baird	Outperform
Mar-19-18	Initiated	Evercore ISI	Outperform
Mar-19-18	Initiated	Jefferies	Buy
Jan-16-18	Reiterated	H.C. Wainwright	Buy
May-30-17	Initiated	Rodman & Renshaw	Buy
Aug-05-16	Resumed	ROTH Capital	Buy
Aug-12-15	Initiated	JMP Securities	Mkt Outperform
Jul-27-15	Initiated	Oppenheimer	Outperform
Jul-22-15	Initiated	ROTH Capital	Buy

View All

Palvella Therapeutics Inc Stock (PVLA) Latest News

Aug 14, 2026

PRUDENTIAL FINANCIAL INC Establishes New Position in Palvella Therapeutics Inc (PVLA) - GuruFocus

Aug 14, 2026

Aug 12, 2026

Palvella at Canaccord Genuity’s 46th Annual Growth Conference: launch prep By Investing.com - Investing.com Canada

Aug 12, 2026

Aug 11, 2026

Palvella (PVLA) Q2 2026 Earnings Call Transcript - AOL.com

Aug 11, 2026

Aug 09, 2026